From medicalnewstoday.com
()
CEO Richard Clark
CEO Richard Clark has been the chief executive officer of Merck & Co since 2005. He is 59 years old. Follow Mr. Clark and Merck & Co in the news and blogs or share your own opinion about the company and its leadership.
The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.
- Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase Ii... (businesswire.com)
Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market, according to new data.
From ivanhoe.com
()
- Vioxx trial data shows early cardiovascular risk (sciencedaily.com)
Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of...
From news-medical.net
()
- Idera, Novartis deal ends; Merck deal extended (masshightech.com)
- Merck & Co Inc-Financial Company Report (pr-inside.com)
We have long been writing about the links between Merck’s blockbuster nonsteroidal, anti-inflammatory medication Vioxx (rofecoxib) and negative cardiac events. Now, according to Science Daily, a study has found that evidence of cardiovascular risks linked to Vioxx might have been realized almost four years before Merck & Co. Inc., pulled the drug from the market. Vioxx [...]
From personalinjurylawnews.com
()
- Vioxx risks could have been detected earlier: study (reuters.com)
Evidence that the painkiller Vioxx might increase the risk of heart attacks and strokes emerged nearly four years before the drug was voluntarily withdrawn from the market, research has shown.
Vioxx, the brand name for rofecoxib, was designed to fight the pain of arthritis. It was launched in May 1999 by Merck & Co Inc. But in September 2004, Merck voluntarily pulled Vioxx following a large trial that was halted early after finding evidence...
From sott.net
()
- Merck wins summary judgment in Texas lawsuit (marketwatch.com)
- Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA (rss.prnewswire.com)
